Corcept Therapeutics Incorporated
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Corcept Therapeutics Incorporated generated cash of $127,039,000, which is more than the previous year. Cash used in financing activities reached the amount of -$148,723,000 last year. Net change in cash is therefore $69,222,000.
Cash Flow
| 2014 | -27.37M | -174K | -3.07M |
|---|---|---|---|
| 2015 | 3.13M | -17K | 13.07M |
| 2016 | 18.39M | -194K | -7.09M |
| 2017 | 60.93M | -73.45M | -7.95M |
| 2018 | 115.66M | -90.76M | -14.33M |
| 2019 | 136.11M | -117.82M | -28.64M |
| 2020 | 151.97M | -119.26M | 12.21M |
| 2021 | 167.89M | 136.12M | -302.59M |
| 2022 | 120.32M | -114.32M | -17.28M |
| 2023 | 127.03M | 90.90M | -148.72M |
CORT Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 66.32M | 77.61M | 76.19M | 31.26M | 41.62M | 31.06M | 51.53M | 40.43M | 24.24M | 54.87M |
Operating activities | ||||||||||
Net income | 106.14M | 101.41M | 112.51M | 106.01M | 94.18M | 75.41M | 129.12M | 8.14M | -6.40M | -31.38M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 2.36M | 2.96M | 3.06M | 2.23M | 2.17M | 236K | 106K | 87K | 155K | 141K |
Stock-based compensation expense | 48.94M | 42.44M | 42.93M | 33.53M | 29.31M | 0 | 13.36M | 7.05M | 6.01M | 5.20M |
| Deferred income tax benefit | 48.94M | 42.44M | 42.93M | 33.53M | 29.31M | 0 | 13.36M | 7.05M | 6.01M | 5.20M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -10.06M | -3.43M | -1.42M | -6.27M | -2.34M | -2.28M | -5.44M | -3.63M | -2.88M | -1.90M |
Inventories | 1.26M | 1.19M | 3.44M | -3.51M | -1.04M | -7.77M | -2.26M | -682K | 815K | 249K |
Accounts payable | 5.77M | 4.75M | -3.59M | 3.16M | -735K | -389K | 6.28M | 965K | -561K | -495K |
Cash generated by operating activities | 127.03M | 120.32M | 167.89M | 151.97M | 136.11M | 115.66M | 60.93M | 18.39M | 3.13M | -27.37M |
Investing activities | ||||||||||
Purchases Of Investments | -328.74M | -355.06M | -312.80M | -420.11M | -299.03M | -233.12M | -73.03M | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -139K | -413K | -469K | -1.23M | -1.08M | -298K | -419K | -194K | -17K | -174K |
Acquisitions Net | 0 | 113.91M | -136.59M | 118.02M | 116.74M | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 90.90M | -114.32M | 136.12M | -119.26M | -117.82M | -90.76M | -73.45M | -194K | -17K | -174K |
Financing activities | ||||||||||
Common Stock Issued | 5.81M | 4.38M | 16.22M | 23.22M | 0 | 0 | 7.18M | 0 | 22.28M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -145.42M | -21.66M | -295.98M | -9.94M | -30.97M | -23.65M | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -2.02M | -1.68M | 0 | 0 | -15.13M | -14.77M | -9.20M | -4.85M |
Cash used in financing activities | -148.72M | -17.28M | -302.59M | 12.21M | -28.64M | -14.33M | -7.95M | -7.09M | 13.07M | -3.07M |
Net Change In Cash | 69.22M | -11.28M | 1.42M | 44.92M | -10.35M | 10.56M | -20.47M | 11.10M | 16.18M | -30.62M |
Cash at end of period | 135.55M | 66.32M | 77.61M | 76.19M | 31.26M | 41.62M | 31.06M | 51.53M | 40.43M | 24.24M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |